2. Search Result
Search Result
Results for "

Melanoma Metastasis

" in MedChemExpress (MCE) Product Catalog:

80

Inhibitors & Agonists

3

Peptides

2

Inhibitory Antibodies

3

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121524
    DJ101

    		Microtubule/Tubulin Cancer
    DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research .
    DJ101
  • HY-121750
    CCG-222740

    		Ras ROCK Cancer
    CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor . CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis .
    CCG-222740
  • HY-B0963
    Cloxiquine
    1 Publications Verification

    5-Chloro-8-quinolinol

    		 Bacterial Fungal Parasite PPAR Infection Cancer
    Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ .
    Cloxiquine
  • HY-156483
    TT-012
    2 Publications Verification

    		 Others Cancer
    TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .
    TT-012
  • HY-156247
    IVMT-Rx-3

    		SDCBP NF-κB MMP Cancer
    IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis [1]
    IVMT-Rx-3
  • HY-124875
    Arylsulfonamide 64B

    HIF inhibitor 64B

    		 HIF/HIF Prolyl-Hydroxylase Neurological Disease
    Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the hypoxia-induced factor (HIF). Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma mouse model .
    Arylsulfonamide 64B
  • HY-P991609
    ABX-MA1

    		MMP Cancer
    ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
    ABX-MA1
  • HY-176347S
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2

    		Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-120241
    Reticulol

    K 251-1

    		 Phosphodiesterase (PDE) Cancer
    Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
    Reticulol
  • HY-119261
    Ruboxyl

    		Antibiotic Cancer
    Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .
    Ruboxyl
  • HY-119933
    RIPK1-IN-7

    		RIP kinase Cancer
    RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .
    RIPK1-IN-7
  • HY-112052
    Aminomalonic acid
    1 Publications Verification

    		 Endogenous Metabolite Cancer
    Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of L-asparagine synthetase from Leukemia 5178Y/AR (Ki= 0.0023 M) and mouse pancreas (Ki= 0.0015 M) in vitro. Aminomalonic acid is a potential biomarker to discriminate between different stages of melanoma metastasis .
    Aminomalonic acid
  • HY-B0963R
    Cloxiquine (Standard)

    5-Chloro-8-quinolinol (Standard)

    		 Reference Standards Bacterial Fungal Parasite PPAR Infection Cancer
    Cloxiquine (Standard) is the analytical standard of Cloxiquine. This product is intended for research and analytical applications. Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ .
    Cloxiquine (Standard)
  • HY-118487
    OB-24
    1 Publications Verification

    		 Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Cancer
    OB-24 is a selective small-molecule HO-1 inhibitor (IC50 = 1.9 μM for HO-1 and IC50 for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis .
    OB-24
  • HY-112052R
    Aminomalonic acid (Standard)

    		Reference Standards Endogenous Metabolite Cancer
    Aminomalonic acid (Standard) is the analytical standard of Aminomalonic acid (HY-112052). This product is intended for research and analytical applications. Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of L-asparagine synthetase from Leukemia 5178Y/AR (Ki= 0.0023 M) and mouse pancreas (Ki= 0.0015 M) in vitro. Aminomalonic acid is a potential biomarker to discriminate between different stages of melanoma metastasis .
    Aminomalonic acid (Standard)
  • HY-139061
    Palmitoyl 3-carbacyclic phosphatidic acid

    		LPL Receptor ROCK Cancer
    Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .
    Palmitoyl 3-carbacyclic phosphatidic acid
  • HY-P11018
    (123B9)2-L2-PTX

    		Peptide-Drug Conjugates (PDCs) Ephrin Receptor Cancer
    (123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .
    (123B9)2-L2-PTX
  • HY-P99781
    Plozalizumab

    MLN-1202

    		 CCR Inflammation/Immunology Cancer
    Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Plozalizumab
  • HY-117231
    RM 06

    		Others Cancer
    RM 06 is an immunomodulator with a peptidyl hypoxanthine structure that significantly reduces the number of lung metastases of B16 melanoma cells in mice after lethal irradiation and bone marrow reconstitution by stimulating the activity of natural killer (NK) cells .
    RM 06
  • HY-150158
    TMX-201

    		Toll-like Receptor (TLR) Cancer
    TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research .
    TMX-201
  • HY-P11011
    Peptide R54

    Pep R54; CXCR4 antagonist peptide 19

    		 CXCR Cancer
    Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
    Peptide R54
  • HY-17357
    Nepafenac

    AHR 9434; AL 6515

    		 COX Prostaglandin Receptor Endogenous Metabolite Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Nepafenac (AHR 9434; AL 6515), a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries .
    Nepafenac
  • HY-17357R
    Nepafenac (Standard)

    AHR 9434 (Standard); AL 6515 (Standard)

    		 Reference Standards COX Prostaglandin Receptor Endogenous Metabolite Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Nepafenac (AHR 9434; AL 6515) (Standard) is the analytical standard of Nepafenac (HY-17357). This product is intended for research and analytical applications. Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
    Nepafenac (Standard)
  • HY-156500
    ICMT-IN-1

    		ICMT Cancer
    ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC50=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
    ICMT-IN-1
  • HY-155433
    ICMT-IN-30

    		ICMT Cancer
    ICMT-IN-30 (compound 67) is an inhibitor of ICMT (IC50=0.27 μM) .
    ICMT-IN-30
  • HY-157092A
    (S)-ICMT-IN-3

    		ICMT Cancer
    (S)-ICMT-IN-3 (compound ent 1-27) is an inhibitor of ICMT (IC50=0.23 μM) .
    (S)-ICMT-IN-3
  • HY-155431
    ICMT-IN-28

    		ICMT Cancer
    ICMT-IN-28 (compound 65) is an inhibitor of ICMT (IC50=0.008 μM) .
    ICMT-IN-28
  • HY-157120
    ICMT-IN-52

    		ICMT Cancer
    ICMT-IN-52 (compound 44) is an inhibitor of ICMT (IC50=0.052 μM) .
    ICMT-IN-52
  • HY-155419
    ICMT-IN-5

    		ICMT Cancer
    ICMT-IN-5 (compound 46) is an inhibitor of ICMT (IC50=0.3 μM) .
    ICMT-IN-5
  • HY-157103
    ICMT-IN-34

    		ICMT Cancer
    ICMT-IN-34 (compound 39) is an inhibitor of ICMT (IC50=0.17 μM) .
    ICMT-IN-34
  • HY-157119
    ICMT-IN-51

    		ICMT Cancer
    ICMT-IN-51 (compound 43) is an inhibitor of ICMT (IC50=0.55 μM) .
    ICMT-IN-51
  • HY-149705
    ICMT-IN-7

    		ICMT Cancer
    ICMT-IN-7 (compound 74) is an inhibitor of ICMT (IC50=0.015 μM). ICMT-IN-7 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
    ICMT-IN-7
  • HY-157095
    ICMT-IN-6

    		ICMT Cancer
    ICMT-IN-6 (compound 29) is an inhibitor of ICMT (IC50=0.09 μM) .
    ICMT-IN-6
  • HY-157118
    ICMT-IN-50

    		ICMT Cancer
    ICMT-IN-50 (compound 3) is an inhibitor of ICMT (IC50=0.31 μM) .
    ICMT-IN-50
  • HY-155429
    ICMT-IN-24

    		ICMT Cancer
    ICMT-IN-24 (compound 63) is an inhibitor of ICMT (IC50=0.19 μM) .
    ICMT-IN-24
  • HY-155424
    ICMT-IN-15

    		ICMT Cancer
    ICMT-IN-15 (compound 51) is an inhibitor of ICMT (IC50=0.032 μM) .
    ICMT-IN-15
  • HY-155422
    ICMT-IN-13

    		ICMT Cancer
    ICMT-IN-13 (compound 49) is an inhibitor of ICMT (IC50=0.47 μM) .
    ICMT-IN-13
  • HY-157114
    ICMT-IN-46

    		ICMT Cancer
    ICMT-IN-46 (compound 25) is an inhibitor of ICMT (IC50=0.556 μM) .
    ICMT-IN-46
  • HY-157105
    ICMT-IN-37

    		ICMT Cancer
    ICMT-IN-37 (compound 41) is an inhibitor of ICMT (IC50=0.308 μM) .
    ICMT-IN-37
  • HY-155430
    ICMT-IN-27

    		ICMT Cancer
    ICMT-IN-27 (compound 64) is an inhibitor of ICMT (IC50=0.1 μM) .
    ICMT-IN-27
  • HY-155427
    ICMT-IN-20

    		ICMT Cancer
    ICMT-IN-20 (compound 54) is an inhibitor of ICMT (IC50=0.682 μM) .
    ICMT-IN-20
  • HY-157112
    ICMT-IN-44

    		ICMT Cancer
    ICMT-IN-44 (compound 23) is an inhibitor of ICMT (IC50=0.167 μM) .
    ICMT-IN-44
  • HY-157092B
    (R)-ICMT-IN-3

    		ICMT Cancer
    (R)-ICMT-IN-3 (compound ent 2-27) is an inhibitor of ICMT (IC50=0.01 μM) .
    (R)-ICMT-IN-3
  • HY-157104
    ICMT-IN-36

    		ICMT Cancer
    ICMT-IN-36 (compound 40) is an inhibitor of ICMT (IC50=0.181 μM) .
    ICMT-IN-36
  • HY-149706
    ICMT-IN-12

    		ICMT Cancer
    ICMT-IN-12 (compound 78) is an inhibitor of ICMT (IC50=0.42 μM) .
    ICMT-IN-12
  • HY-157096
    ICMT-IN-8

    		ICMT Cancer
    ICMT-IN-8 (compound 30) is an inhibitor of ICMT (IC50=0.652 μM) .
    ICMT-IN-8
  • HY-149707
    ICMT-IN-21

    		ICMT Cancer
    ICMT-IN-21 (compound 6ag) is an ICMT inhibitor (IC50=8.8 μM), a sulfonamide-modified farnesyl cysteine (SMFC). The farnesyl and carboxylic acid motifs of ICMT-IN-21 are important structures for inhibiting ICMT .
    ICMT-IN-21
  • HY-155425
    ICMT-IN-17

    		ICMT Cancer
    ICMT-IN-17 (compound 52) is an inhibitor of ICMT (IC50=0.38 μM) .
    ICMT-IN-17
  • HY-157102
    ICMT-IN-26

    		ICMT Cancer
    ICMT-IN-26 (compound 38) is an inhibitor of ICMT (IC50=0.36 μM) .
    ICMT-IN-26
  • HY-157098
    ICMT-IN-16

    		ICMT Cancer
    ICMT-IN-16 (compound 33) is an inhibitor of ICMT (IC50=0.131 μM) .
    ICMT-IN-16

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: